IHS Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Demonstrate the potential of pharmaceuticals, biotechnology products, medical devices and care delivery patterns on patient health outcomes, medical costs, productivity and quality of life
Identify and quantify key cost drivers to develop efficient, evidence-based estimates for reimbursement and prospective payment
Healthcare Pricing Models
Develop the optimal new drug price and market entry strategy
Market Entry Analysis
Receive continuous analysis, data and online tools covering technology, reimbursement, regulations, geographic/therapeutic segment scenarios
Partner with us for customized research on business improvement and opportunity maximization strategies
Access customized research at less cost by participating in multi-client, syndicated market research that employs qualitative and quantitative surveys, market access scenarios and market analysis
Integrating HTA Requirements into Oncology R&D Process
A pharmaceutical company needed recommendations for incorporating more HTA considerations into R&D decision-making.
We researched recent HTA decisions in Australia, US, United Kingdom, France, Germany, Italy and Spain in the client’s four therapeutic areas. Our detailed case studies identified the choice of trial design, trial comparator, patient group selection, primary and secondary outcome measures, strength of correlation between surrogate and final outcomes, traits of PRO evidence and studies, and a definition of clinical relevance.
We helped the client build user-friendly HTA "checklists". The client uses these checklists to ensure its R&D personnel factor HTA considerations into future planning.
Millions of lives are saved by blood transfusions and this company plays a vital role in making transfusions safe. To provide hospitals with the best pre-transfusion diagnostic products, its researchers are identifying next-generation concepts and generating important innovations while also resolving problems and documenting their findings more efficiently.
A top manufacturer of medical supplies reduced commodity costs by millions of dollars within 18-20 months and enabled its team to negotiate better rates – e.g., pushing back on 6 commodity cost increases in 8 months due to more accurate pricing data. Enabling tighter forecasts and improving workflows helps the company serve consumers more effectively.
One of the world’s largest oilfield service providers enhanced the forecasting accuracy of its oil rig count model from 90 to 97.6 percent, predicted the impact of price changes on customer spending and demand for product lines (by leveraging 3,500 factors) and created a model that predicted the deflation of WTI crude oil prices in late 2014.
This premier aircraft manufacturer produced Flying on Demand, Global Market Forecast 2014-2033, a reference book that provides comprehensive economic, financial and political coverage of 200-plus countries. Stakeholders throughout the commercial airline industry rely on the book’s insights regarding product innovation, production and planning.
Whilst in the midst of research into our next multi-client study, Pathways to Precision Medicine: Navigating Payer Needs and Healthcare Systems through Molecular Diagnostics, I have encountered an ambitious proposal driven by two prominent medical societies- the Spanish Medical Oncology Society, SEOM, and the Spanish Soci..more
Among the markets in Latin America, Brazil is a leader in implementing a strategy of building up a domestic pharma industry through Productive Development Partnerships (PDPs). Last week, Brazil's ministry of health published a detailed report addressing the key achievements of the PDPs and the prospects of the coming PDPs under new ..more
‘and we’ve come so far’……The opening line of Take That’s 1995 classic chart toping hit Never Forget, could have fit perfectly for the launch of UNAIDS' latest report on the fight against HIV. There was also likely lots of slapping on the back as the rather extensive report laid down plenty of good news. We learnt that rates of new infection are now falli..more
A national cancer biomarker platform in Spain: When will it become a reality? http://t.co/oWRXxxJVZe
Transforming the Brazilian domestic pharma industry through PDPs http://t.co/CN9qcpgdeP
Does the UNAIDS report whitewash over the very real funding crisis facing HIV treatment programs? http://t.co/flAGABKwsG
Follow Life Sciences Consulting @IHS4LifeScience